Matinas BioPharma Holdings, Inc. (MTNB)
NYSEAMERICAN: MTNB · IEX Real-Time Price · USD
0.179
0.00 (-0.06%)
Jul 19, 2024, 4:00 PM EDT - Market closed
MTNB Employees
Matinas BioPharma Holdings had 32 employees as of December 31, 2023. The number of employees decreased by 2 or -5.88% compared to the previous year.
Employees
32
Change (1Y)
-2
Growth (1Y)
-5.88%
Revenue / Employee
n/a
Profits / Employee
-$726,656
Market Cap
44.97M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Qilian International Holding Group | 298 |
Carisma Therapeutics | 107 |
BioXcel Therapeutics | 74 |
Lucid Diagnostics | 70 |
Kezar Life Sciences | 58 |
Protara Therapeutics | 27 |
Regencell Bioscience Holdings | 12 |
CalciMedica | 12 |
MTNB News
- 4 weeks ago - Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program - GlobeNewsWire
- 5 weeks ago - Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. - GlobeNewsWire
- 2 months ago - New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024 - GlobeNewsWire
- 2 months ago - Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 2 months ago - Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024 - GlobeNewsWire
- 3 months ago - Matinas BioPharma Prices $10 Million Registered Direct Offering - GlobeNewsWire
- 4 months ago - Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update - GlobeNewsWire
- 4 months ago - Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation - GlobeNewsWire